Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
GSK2857916 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).
SEA-BCMA is a new antibody targeting the BCMA protein and being tested in multiple myeloma.
SGN-CD48A is a novel humanized anti-cd48 antibody-drug conjugate being tested for the treatment of multiple myeloma.
An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.
AMG-224 is a new drug being tested in myeloma called an antibody-drug conjugate comprised of anti-BCMA–MCC–DM1. It consists of a chemotherapy drug combined with a monoclonal antibody which helps to deliver the drug to myeloma cells.
FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46.
MEDI2228 is a novel antibody drug conjugate that targets BCMA.
SGN-CD352A is an antibody drug conjugate that can work by targeting specific areas of the cancer cell, attacking it, and inducing rapid cell death.
Create your account today and get matched to myeloma treatments and trials around the US.
Weekdays 9am - 5pm EST